OncoSec Medical Incorporated · OTC:ONCSQ
OncoSec Medical — Investor Presentation (April 2023)
33 slides from OncoSec Medical's investor presentation, April 2023
Slide 1: Corporate Update
Corporate Update Non-Confidential Presentation April 2023
Slide 2: Risk Factors and Forward-Looking Statements
Risk Factors and Forward-Looking Statements This presentation contains forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Forward-looking statements provide the Com
Slide 3: Awakening the immune system to eradicate cancer
Awakening the immune system to eradicate cancer • Proprietary TAVO™ electroporation platform to elicit tumor-directed immune cell activation by stimulating the patient’s immune system without neoantigen delivery • Intra-tumoral delivery of interleukin 12 plasmid to cutaneous, subcutaneous and nodal
Slide 4: OncoSec as a future leader of immuno-oncology therapy
OncoSec as a future leader of immuno-oncology therapy Addressing unmet clinical needs by leveraging innovative intratumoral drug delivery Vision • We aspire to awaken the immune system to eradicate cancer and restore patients’ lives. Mission • Provide safe and effective solutions for cancer patients
Slide 5: TAVO-EP platform designed to address key clinical unmet needs
TAVO™-EP platform designed to address key clinical unmet needs • Unique intratumoral delivery applicable to cutaneous, Plasmid Electrode Gene subcutaneous, and nodal lesions 1 Injection 2 Insertion 3 Delivery • Demonstrated clinical activity for patients who have progressed on checkpoint inhibitors
Slide 6: TAVO-EP plus KEYTRUDA - rationale for neoadjuvant melanoma
TAVO™-EP plus KEYTRUDA® - rationale for neoadjuvant melanoma Going beyond immune checkpoint inhibitors and cancer vaccines, neoadjuvant melanoma represents promising option for patients with advanced melanoma1 • TAVO™-EP in the neoadjuvant setting offers a novel “personalized off-the-shelf therapeut
Slide 7: The IO market driven by checkpoint inhibitors is growing rapidly
The IO market driven by checkpoint inhibitors is growing rapidly Global Market Analysis and Forecast of Immuno-Oncology (IO) Approaches • Immuno-oncology (IO) approaches have 160 $143 B demonstrated significant, durable response 140 rates in a broad range of cancer types 120 Market Value ($B) CAGR 2
Slide 8: Despite IO success, great unmet need remains in melanoma
Despite IO success, great unmet need remains in melanoma Primary Resistance Secondary Resistance Most patients receive PD-1 mono- Among initial PD-1 responders, or combination therapy in first ~40% acquire resistance and line, yet 40 – 65% fail to respond1 progress within 5 years2 Key Unmet Needs Po
Slide 9: Cancer vaccines aim to induce cancer immunity to close ICI gap
Cancer vaccines aim to induce cancer immunity to close ICI gap • Cancer vaccines induce cancer immunity by educating immune effector cells to recognize selected tumor neoantigens or shared tumor-associated antigens provided as therapeutic modality • Personalized vaccines deliver autologous cancer an
Slide 10: TAVO-EP IL-12 in situ vaccination to awaken the immune system
Melanoma: Neoadjuvant Melanoma: Advanced TAVO™-EP IL-12 in situ vaccination to awaken the immune system TAVO™ Cancer antigen TAA-presenting presenting APC APC ● ● ● Tumor ● ● cell ● ●● APC-mediated T cell activation ● in presence of IL-12 Draining lymph node Local release of tumor TAA-specific antig
Slide 11: TAVO-EP has substantial clinical activity and safety data
TAVO™-EP has substantial clinical activity and safety data • TAVO™-EP has been studied in clinical trials as mono- and combination therapy • TAVO™-EP was administered in most trials as 3 treatments per cycle in 6-week cycles • TAVO™-EP has been administered to more than 230 melanoma patients and ove
Slide 12: Sharpened focus on melanoma and potential in other tumor types
Melanoma: Neoadjuvant Melanoma: Advanced Triple Negative Breast Sharpened focus on melanoma and potential in other tumor types Regimen Trial Indication Partner Phase 1 Phase 2 Pivotal TAVO™ + OMS-104 Neoadjuvant Resectable Locally / recruiting Key Focus Nivolumab Phase 2 IST1 Regionally Advanced Mel
Slide 13: Neoadjuvant melanoma therapy is gaining traction
Melanoma: Neoadjuvant Melanoma: Advanced Neoadjuvant melanoma therapy is gaining traction… Southwest Oncology Group (SWOG) trial S1801 Phase 2, n= 313 • Pembrolizumab monotherapy (200 mg IV, Q3W) − Neoadjuvant (3 doses) and adjuvant (15 doses) vs. − Adjuvant (18 doses) • Primary endpoint EFS: − Land
Slide 14: But not all patients benefit from neoadjuvant ICI combinations
Melanoma: Neoadjuvant Melanoma: Advanced …but not all patients benefit from neoadjuvant ICI combinations OpACIN-neo trial (Phase 2, n=89) • Ipilimumab plus nivolumab (various dose regimens) • IFN-g signature and tumor mutational burden (TMB) in baseline tumors predicted better clinical outcomes. − P
Slide 15: SITC 2022 Neoadjuvant Immunotherapy with Intratumoral TAVO plus EP and Nivolumab
SITC 2022 Melanoma: Neoadjuvant Melanoma: Advanced Neoadjuvant Immunotherapy with Intratumoral Tavokinogene Telseplasmid (TAVO) plus Electroporation (EP) in Combination with Intravenous Nivolumab in Patients with Operable Locoregionally Advanced Melanoma 1Ahmad A Tarhini, MD, PhD; 1Zeynep Eroglu, MD
Slide 16: Neoadjuvant melanoma Phase 2 IST design and endpoints
SITC 2022 Melanoma: Neoadjuvant Melanoma: Advanced Neoadjuvant melanoma Phase 2 IST* design and endpoints • Primary Endpoint: complete pathologic response (pCR) rate • Secondary Endpoints: Near-complete (major) pathologic response (pMR), radiological/clinical preoperative response rate, relapse free
Slide 17: Bulky tumors disappear with treatment
SITC 2022 Melanoma: Neoadjuvant Melanoma: Advanced Bulky tumors disappear with treatment Day 1 Day 8 Day 28 Day 85 (Cycle 1) (Cycle 1) (Cycle 2 Day 1) (right before surgery) RECIST v1.1 CR Pathologic CR 17
Slide 18: High pathological major response rate with TAVO-EP + nivolumab
SITC 2022 Melanoma: Neoadjuvant Melanoma: Advanced High pathological major response rate with TAVO™-EP + nivolumab Patient Disease Baseline Tumor No. of TAVO-EP No. of Nivo Cycles Radiological Preoperative Pathological Response‡ # Stage Biomarkers Full treatment = 6-9* Full treatment = 3 RECIST v1.1
Slide 19: TAVO-EP Phase 2 neoadjuvant IST: predictive biomarkers
Melanoma: Neoadjuvant Melanoma: Advanced TAVO™-EP Phase 2 neoadjuvant IST: predictive biomarkers Baseline biomarkers predicting no or limited responses to anti-PD-1 mAb in majority of patients • Tumor infiltrating lymphocytes (TIL) are essential for anti-tumor immune responses by producing cytokines
Slide 20: Inflammatory biomarker changes as early signs of clinical activity
Melanoma: Neoadjuvant Melanoma: Advanced Inflammatory biomarker changes as early signs of clinical activity Peritumoral CD8+ CD8+ TIL 100 100 (within inflammatory population) 1 (non-responder) 80 80 Predictive biomarker signals change with treatment 2 (peritumoral) Enrolled patients (n=15); % CD8+ 3
Slide 21: Summary of TAVO-EP Phase 2 IST in neoadjuvant melanoma
SITC 2022 Melanoma: Neoadjuvant Melanoma: Advanced Summary of TAVO™-EP Phase 2 IST* in neoadjuvant melanoma • Intratumoral TAVO™-EP in combination with nivolumab in neoadjuvant melanoma exhibits encouraging clinical activity and a favorable safety profile • Pathologic complete response (pCR) rate 66
Slide 22: TAVO-EP melanoma neoadjuvant summary
Melanoma: Neoadjuvant Melanoma: Advanced TAVO™-EP melanoma neoadjuvant summary Challenges Opportunities • ICI followed by surgery is not approved but may become SOC • Currently no approved therapies • Ipi/nivo has ~50% pathological complete response rate (pCR), • Patients start with accessible disea
Slide 23: OncoSec neoadjuvant melanoma Phase 2 randomized trial design
Melanoma: Neoadjuvant Melanoma: Advanced OncoSec neoadjuvant melanoma Phase 2 randomized trial design Pembrolizumab ± TAVO™-EP Neoadjuvant Definitive Surgery Adjuvant Phase Phase Phase N = 3-15 patients Run-In Surgery & 3 wks 3 wks 3 wks 3 wks Run-In Stage Resectable locally- Select Arm A dosing reg
Slide 24: Run-In Design to assess TAVO-EP dosing regimen for Ph2 RCT
Melanoma: Neoadjuvant Melanoma: Advanced Run-In Design to assess TAVO™-EP dosing regimen for Ph2 RCT PLANNING & FDA MEETING RUN-IN STAGE RANDOMIZATION 1H2023 4-10 months to interim data read-out 5 years • Ad Board meetings April 2023 • FDA meeting to discuss May 2023 − Study design D1 TAVO™-EP Patho
Slide 25: TAVO-EP Phase 2 neoadjuvant melanoma trial (draft design)
Melanoma: Neoadjuvant Melanoma: Advanced TAVO™-EP Phase 2 neoadjuvant melanoma trial (draft design) Key eligibility criteria: Resectable stage III (B-D), surgery surgery accessible for electroporation TAVO + total subjects SOC adjuvant pembrolizumab (Q6W) N = 84 (1:1) pembro Stratification factors:
Slide 26: KEYNOTE-695 Phase 2 in PD-1 refractory melanoma overview
Melanoma: Neoadjuvant Melanoma: Advanced KEYNOTE-695 Phase 2 in PD-1 refractory melanoma overview Key Eligibility • Stage III/IV melanoma, target N = 152, ~30 global sites TAVO + pembrolizumab Survival Follow-up • ≥12 weeks of anti-PD-1 therapy, with documented disease progression within 12 weeks of
Slide 27: KEYNOTE-695 Phase 2: Cohort 1a BICR summary
Melanoma: Neoadjuvant Melanoma: Advanced KEYNOTE-695 Phase 2: Cohort 1a BICR summary • The primary endpoint of KEYNOTE-695, overall response rate (ORR) by blinded independent central review (BICR), was not met. BICR ORR1 of 10.2% (95% CI 5.00, 17.97%), including 4 CR and 6 PR, did not achieve the pr
Slide 28: TAVO-EP 2023 milestones
Melanoma: Neoadjuvant Melanoma: Advanced TAVO™-EP 2023 milestones • Discussions with Regulatory Agencies regarding melanoma neoadjuvant [May 2023] • TAVO™-EP Phase 2 RCT in neoadjuvant melanoma initiation [4Q2023] • TAVO™-EP Phase 2 IST in neoadjuvant melanoma data update at upcoming medical meeting
Slide 29: Global intratumoral cancer therapy market growth
Global intratumoral cancer therapy market growth • Several independent studies show that the intratumoral cancer therapy market grows rapidly ⁻ monoclonal antibodies, vaccines, checkpoint Inhibitors, cell therapies, immune system modulators, adoptive cell transfer, cytokines, and others (left panel)
Slide 30: OncoSec beyond TAVO-EP: Visceral Lesion Applicator (VLA)
OncoSec beyond TAVO™-EP: Visceral Lesion Applicator (VLA) VLA Organ Plasmid Gene (preclinical prototype) 1 Entry 2 Injection 3 Delivery 1.27mm DIAMET ER INSULAT OR RING BEVELED T IP SIDE INJECT ION PORT S • Applicable to solid tumors located deep inside the body through our unique intra-tumoral deli
Slide 31: Investment opportunity
Investment opportunity Differentiated Best-in-class Robust Development Intra-tumoral Platform Therapeutic Potential Strategy TAVO™ designed to Experienced overcome key immuno- Neoadjuvant Melanoma management team and therapy shortcomings, with encouraging key strategic partnerships with improved saf
Slide 32: Experienced industry leaders with track record of success
Experienced industry leaders with track record of success Leadership Team Board of Directors Linda Shi, M.D. Robert H. Arch, Ph.D Chair George Chi Robert H. Arch, Ph.D. President and Chief Financial Officer Director Chief Executive Officer Stephany Foster, M.B.A. Director Bridget O’Keeffe, Ph.D Robe
Slide 33: Thank You
®)oncosec IMMUNOTHERAPIES THANK YOU!